Sympathetic nerve activator and sympathetic nerve activating composition

Abstract

Provided is a sympathetic nerve activator comprising a compound represented by structural formula (1).

Description

Technical Field

[0001] The present invention relates to a sympathetic nerve activator and a composition for sympathetic nerve activating. Background Art

[0002] Stress has become a big problem in recent years. External stimulation of the body and mind is called stress response. There are physical stress responses such as weather, temperature changes, noise, chemical stress responses such as drugs and harmful chemicals, psychological and social stress responses such as interpersonal relationships, work problems, and family problems.

[0003] In order to keep the internal environment of the body constant in response to external stimuli, there is a system called the autonomic nervous system in the body. The autonomic nervous system includes the sympathetic nervous system and the parasympathetic nervous system.

[0004] When the sympathetic nerves are stimulated, it increases the heart rate, constricts blood vessels, and reduces gastrointestinal function. Through the activation of the sympathetic nerves, it can be expected to have the effect of clearing the mind, reducing drowsiness, and maintaining concentration.

[0005] Hitherto, cyclopropyl-phenylalanine, which is a cyclic dipeptide, has been reported as a component that activates sympathetic nerves (for example, see Patent Document 1).

[0006] However, there is still a strong demand for new raw materials that have a sympathetic nerve activating effect and are highly safe and can be widely used as components of foods, beverages, pharmaceuticals, research reagents, etc., and the current situation is that there is a demand for rapid development thereof.

[0007] In addition, the name of the compound represented by the following structural formula (1) is 3-(4-hydroxy-3-methoxyphenyl)propionic acid (English name: 3-(4-Hydroxy-3-methoxyphenyl)propionic acid). It is known that the compound represented by the following structural formula (1) is detected when a certain type of lactic acid bacteria is cultured using a culture medium containing specific components (for example, refer to Patent Document 2).

[0008] [Chemistry 1]

[0009]

[0010] The compound represented by the structural formula (1) is an effective ingredient of a dipeptidyl peptidase IV activity inhibitor and is known to be a very useful ingredient that can be added to foods and beverages for inhibiting dipeptidyl peptidase IV activity (for example, see Patent Document 3).

[0011] However, it is not known that the compound represented by the above structural formula (1) has a sympathetic nerve activating effect.

[0012] Prior art literature

[0013] Patent Literature

[0014] Patent Document 1: Japanese Patent Application Publication No. 2022-048337

[0015] Patent Document 2: Japanese Patent Application Publication No. 2014-003929

[0016] Patent Document 3: Japanese Patent Application Publication No. 2020-055887 Summary of the invention

[0017] Problem that the invention aims to solve

[0018] The present invention aims to solve the above-mentioned various conventional problems and achieve the following objectives. Specifically, the present invention aims to provide a sympathetic nerve activating agent and a sympathetic nerve activating composition having excellent sympathetic nerve activating action and high safety.

[0019] Methods used to solve problems

[0020] The present inventors have conducted intensive studies to solve the above problems and have found that the compound represented by the following structural formula (1) has an excellent sympathetic nerve activating effect and is highly safe and is useful for sympathetic nerve activating applications.

[0021] [Chemistry 2]

[0022]

[0023] The present invention is based on the above-mentioned knowledge of the present inventors, and as a method for solving the above-mentioned problems, it is as follows. That is,

[0024] <1> A sympathetic nerve activator, comprising a compound represented by the following structural formula (1).

[0025] [Chemistry 3]

[0026]

[0027] <2> The sympathetic nerve activator according to <1> above, wherein the sympathetic nerve is a sympathetic nerve that controls at least one selected from the group consisting of white adipose tissue, brown adipose tissue, adrenal gland, and liver.

[0028] <3> A composition for activating sympathetic nerves, comprising the sympathetic nerve activator according to <1> or <2> above.

[0029] Effects of the Invention

[0030] According to the sympathetic nerve activator and the sympathetic nerve activating composition of the present invention, the above-mentioned various problems of the prior art can be solved, the above-mentioned objects can be achieved, and a sympathetic nerve activator and a sympathetic nerve activating composition having excellent sympathetic nerve activating effect and high safety can be provided. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 This is a graph showing changes in the nerve activity of the centrifugal branches of the epididymal white adipose tissue sympathetic nerves in Test Example 1.

[0032] Figure 2 This is a graph showing changes in the neural activity of the centrifugal branches of the interscapular brown adipose tissue sympathetic nerve in Test Example 1.

[0033] Figure 3 Graph showing changes in nerve activity of the centrifugal branches of the adrenal sympathetic nerves in Test Example 1.

[0034] Figure 4 Graph showing changes in nerve activity of the centrifugal branches of the hepatic sympathetic nerves in Test Example 1. DETAILED DESCRIPTION

[0035] (Sympathetic Nerve Activator)

[0036] The sympathetic nerve activator of the present invention contains the compound represented by the following structural formula (1) as an active ingredient, and further contains other ingredients as necessary.

[0037] [Chemistry 4]

[0038]

[0039] In the present specification, sympathetic nerve activation means increasing the amount of sympathetic nerve activity compared to before administration of the sympathetic nerve activating agent.

[0040] The sympathetic nerve activator preferably activates sympathetic nerves that control at least one selected from the group consisting of white adipose tissue, brown adipose tissue, adrenal gland, and liver.

[0041] It has never been known before that the compound represented by the structural formula (1) has a sympathetic nerve activating action and is useful as a sympathetic nerve activator, but this is a new finding of the present inventors.

[0042] <Compound represented by structural formula (1)>

[0043] The name of the compound represented by the following structural formula (1) is 3-(4-hydroxy-3-methoxyphenyl)propionic acid (English name: 3-(4-Hydroxy-3-methoxyphenyl)propionic acid) (hereinafter sometimes referred to as "HMPA").

[0044] [Chemistry 5]

[0045]

[0046] The compound represented by the above structural formula (1) is a known compound, and a commercially available product may be used, or a compound extracted from a plant or the like may be used.

[0047] The content of the compound represented by the structural formula (1) in the sympathetic nerve activator is not particularly limited and can be appropriately selected depending on the intended purpose.

[0048] The sympathetic nerve activator may be formed only from the compound represented by the above structural formula (1), and the compound represented by the above structural formula (1) may be formulated.

[0049] <Other ingredients>

[0050] As the above-mentioned other components, there are no particular restrictions as long as the effects of the present invention are not impaired, and they can be appropriately selected according to the form of use of the above-mentioned sympathetic nerve activator, and examples thereof include excipients, antiseptics, preservatives, enhancers, thickeners, emulsifiers, antioxidants, sweeteners, acidulants, seasonings, colorants, fragrances, whitening agents, moisturizers, oily components, ultraviolet absorbers, surfactants, alcohols, powder components, colorants, aqueous components, water, skin nutrients, etc. These may be used alone or in combination of two or more.

[0051] The content of the other components in the sympathetic nerve activator is not particularly limited and can be appropriately selected depending on the intended purpose.

[0052] The sympathetic nerve activator can be formulated into any dosage form such as powder, granules, tablets, or liquid using pharmaceutically acceptable carriers such as dextrin and cyclodextrin or any other auxiliary agents according to conventional methods. In this case, auxiliary agents such as excipients, binders, disintegrants, lubricants, stabilizers, flavoring agents, and deodorants can be used.

[0053] The above-mentioned sympathetic nerve activator can be used in combination with other compositions (for example, the sympathetic nerve activating composition described below), and can also be used as parenteral administration such as injections, drops, suppositories, ointments, eye drops, external liquids, patches, etc.

[0054] Furthermore, the sympathetic nerve activator may contain other components having sympathetic nerve activating effects as necessary together with the compound represented by the above structural formula (1) and used as an active ingredient.

[0055] <Application>

[0056] The use of the sympathetic nerve activator is not particularly limited and can be appropriately selected depending on the intended purpose. For example, a wide range of uses such as pharmaceuticals, quasi-drugs, and foods and beverages are exemplified.

[0057] The sympathetic nerve activator has an excellent sympathetic nerve activating effect and is highly safe, and therefore can be suitably used as an active ingredient of a sympathetic nerve activating composition described below, for example.

[0058] The above-mentioned sympathetic nerve activators are suitable for use in humans, but can be used in animals other than humans (eg, mice, rats, hamsters, dogs, cats, cows, pigs, monkeys, etc.) as long as their effects are exerted.

[0059] The above-mentioned sympathetic nerve activator is preferably used for an individual whose sympathetic nerve activity is lower than usual.

[0060] The administration method of the sympathetic nerve activator is not particularly limited and can be appropriately selected depending on the intended purpose. Examples of the administration method include oral administration, parenteral administration, and external application.

[0061] The dosage form of the sympathetic nerve activator is not particularly limited, and a known dosage form can be appropriately selected according to the purpose.

[0062] The method for producing the sympathetic nerve activator in any dosage form is not particularly limited, and a known method can be appropriately selected.

[0063] The administration method, dosage, administration site, administration period, administration interval, etc. of the sympathetic nerve activator are not particularly limited and can be appropriately selected depending on the purpose.

[0064] For example, examples of the dosage of the sympathetic nerve activator for humans include 0.5 mg to 5,000 mg per day per 60 kg of body weight, calculated as the amount of the compound represented by the above structural formula (1).

[0065] In addition, as an example of the dosage of the above-mentioned sympathetic nerve activator to humans when the purpose is to enhance the activity of the sympathetic nerves that control white adipose tissue, the daily dosage, converted into the amount of the compound represented by the above-mentioned structural formula (1), can be 50 mg to 5,000 mg per 60 kg of body weight.

[0066] In addition, as an example of the dosage of the above-mentioned sympathetic nerve activator to humans when the purpose is to enhance the activity of the sympathetic nerves that control brown adipose tissue, the daily dosage, converted into the amount of the compound represented by the above-mentioned structural formula (1), is 5 mg to 5,000 mg per 60 kg of body weight.

[0067] In addition, examples of the dosage of the sympathetic nerve activator for humans for the purpose of enhancing the activity of the sympathetic nerves that control the adrenal glands include 0.5 mg to 5,000 mg per day per 60 kg of body weight, calculated as the amount of the compound represented by the above structural formula (1).

[0068] In addition, examples of the dosage of the sympathetic nerve activator for humans for the purpose of enhancing the activity of the sympathetic nerves controlling the liver include 5 mg to 5,000 mg per day per 60 kg of body weight, calculated as the amount of the compound represented by the above structural formula (1).

[0069] Furthermore, the sympathetic nerve activator of the present invention can be used as a reagent for research related to the action mechanism of sympathetic nerve activation.

[0070] (Composition for activating sympathetic nerves)

[0071] The composition for activating sympathetic nerves of the present invention contains the sympathetic nerve activator of the present invention and further contains other components as necessary.

[0072] <Sympathetic nerve activator>

[0073] The sympathetic nerve activator is the sympathetic nerve activator of the present invention.

[0074] The content of the sympathetic nerve activator in the sympathetic nerve activating composition is not particularly limited and can be appropriately adjusted according to the form of the sympathetic nerve activating composition, and is preferably 0.0001% by mass to 20% by mass, more preferably 0.0001% by mass to 10% by mass, calculated as the amount of the compound represented by the structural formula (1). The sympathetic nerve activating composition may consist solely of the sympathetic nerve activator.

[0075] <Other ingredients>

[0076] The other components in the above-mentioned sympathetic nerve activating composition are not particularly limited and can be appropriately selected according to the use form of the above-mentioned sympathetic nerve activating composition, and for example, the same components as the other components described in the above-mentioned sympathetic nerve activating agent can be mentioned. These can be used alone or in combination of two or more.

[0077] The content of the other components in the sympathetic nerve activating composition is not particularly limited and can be appropriately selected depending on the intended purpose.

[0078] <Form>

[0079] The form of the sympathetic nerve activating composition is not particularly limited and can be appropriately selected depending on the intended purpose. Examples thereof include pharmaceuticals, quasi-drugs, and foods and beverages.

[0080] The above-mentioned composition for activating sympathetic nerves can be used daily, and can extremely effectively exert various physiological activities including sympathetic nerve activation due to the action of the compound represented by the above-mentioned structural formula (1) as an active ingredient.

[0081] The above-mentioned composition for activating sympathetic nerves is suitable for use in humans, but can be used in animals other than humans (eg, mice, rats, hamsters, dogs, cats, cows, pigs, monkeys, etc.) as long as their respective effects are exerted.

[0082] The above-mentioned composition for activating sympathetic nerves is preferably used for individuals whose sympathetic nerve activity is lower than usual.

[0083] The administration method of the composition for activating sympathetic nerves is not particularly limited and can be appropriately selected depending on the intended purpose. Examples of the administration method include oral administration, parenteral administration, and external application, and oral administration is preferred.

[0084] As the composition used for above-mentioned oral use, for example, oral administration agent, diet can be enumerated.Here, so-called diet refers to that the possibility of causing harm to people's health is small, and in common social life, by oral or digestive tract casting and the food taken in, is not limited to the distinction of food, pharmaceuticals, quasi-drugs etc. on administrative division.Therefore, above-mentioned diet refers to the diet of the diet of the general food, health food (functional diet), health function food (specific health food, nutrition function food, functional labeling food), quasi-drugs, pharmaceuticals etc. that widely comprise oral intake.

[0085] There is no particular limitation on the type of the composition for oral administration, and it can be appropriately selected according to the purpose. For example, beverages such as tea beverages, refreshing drinks, carbonated drinks, nutritional drinks, fruit drinks, lactic acid drinks, alcoholic drinks, coffee drinks, and refreshing drinks containing coffee (including concentrated original solutions of these beverages and powders for adjustment); ice cream, smoothies, shaved ice and other ice creams; noodles such as soba noodles, udon noodles, vermicelli noodles, dumpling wrappers, shumai wrappers, Chinese noodles, and instant noodles; desserts such as sugar, candy, chewing gum, chocolate, hard candy, snacks, biscuits, jelly, jam, cream, baked snacks, and bread; marine products such as crabs, salmon, clams, tuna, sardines, shrimps, bonito, Spanish mackerel, whales, oysters, saury, squid, ark shells, scallops, abalone, sea urchins, fish roe, and shellfish; fish cakes, ham, sausages, etc. Processed foods from aquatic and livestock products; dairy products such as processed milk and fermented milk; oils and fats such as salad oil, tempura oil, margarine, mayonnaise, puff pastry, fresh cream, and sauces, and foods processed with oils and fats; seasonings such as sauces and dressings; steamed and cooked foods such as curry, stew, chicken and egg rice, porridge, porridge with stew, Chinese rice, fried pork cutlet rice, tempura rice, eel rice, beef rice, oden, mapo tofu, beef rice, meat sauce, egg soup, omelette rice, dumplings, steamed buns, hamburgers, and meatballs; home-cooked dishes such as salads and pickles; various forms of health, beauty, and nutritional supplements; pharmaceuticals and quasi-pharmaceuticals such as tablets, powders, capsules, granules, extracts, syrups, oral liquids, lozenges, and gargles; oral fresheners and toothpastes used in the mouth such as mouth fresheners and bad breath preventers.

[0086] The method for producing the composition for activating sympathetic nerves is not particularly limited, and can be appropriately selected according to the form of use of the composition for activating sympathetic nerves, and the like.

[0087] The amount, site of use, period of use, interval of use, etc. of the sympathetic nerve activating composition are not particularly limited and can be appropriately selected depending on the intended purpose.

[0088] For example, the dosage of the sympathetic nerve activating composition for human use is 0.5 mg to 5,000 mg per day per 60 kg of body weight, calculated as the amount of the compound represented by the above structural formula (1).

[0089] In addition, as an example of the dosage of the above-mentioned sympathetic nerve activating composition for human use when the purpose is to enhance the activity of the sympathetic nerves that control white adipose tissue, the daily dosage, converted into the amount of the compound represented by the above-mentioned structural formula (1) per 60 kg of body weight, can be 50 mg to 5,000 mg.

[0090] In addition, as an example of the dosage of the above-mentioned sympathetic nerve activating composition for human use when the purpose is to enhance the activity of the sympathetic nerves that control brown adipose tissue, the daily dosage, converted into the amount of the compound represented by the above-mentioned structural formula (1) per 60 kg of body weight, can be 5 mg to 5,000 mg.

[0091] In addition, examples of the dosage of the above-mentioned sympathetic nerve activating composition for human use when the purpose is to enhance the activity of the sympathetic nerves that control the adrenal glands include 0.5 mg to 5,000 mg per day per 60 kg of body weight, calculated as the amount of the compound represented by the above-mentioned structural formula (1).

[0092] In addition, as an example of the dosage of the above-mentioned sympathetic nerve activating composition for human use when the purpose is to enhance the activity of the sympathetic nerves that control the liver, the daily dosage, converted into the amount of the compound represented by the above-mentioned structural formula (1), can be 5 mg to 5,000 mg per 60 kg of body weight.

[0093] As described above, the sympathetic nerve activating agent and the sympathetic nerve activating composition of the present invention have an excellent sympathetic nerve activating action.

[0094] Therefore, the present invention also relates to a method for activating sympathetic nerves, characterized in that at least one selected from the group consisting of the above-mentioned sympathetic nerve activating agent and sympathetic nerve activating composition is administered to an individual.

[0095] When the activity of the sympathetic nerves in the white adipose tissue is increased, the lipase in the white adipose tissue is activated via the β3 adrenergic receptors, promoting lipolysis that decomposes the accumulated neutral fat into fatty acids and glycerol, thereby having a slimming effect of reducing the amount of fat accumulation.

[0096] If the activity of the sympathetic nerves that control the brown adipose tissue increases, the uncoupling protein-1 (UCP-1) present in the mitochondria of the brown adipose tissue is activated through the β3 adrenergic receptor, promoting heat generation and raising body temperature. The heat generation of this tissue uses fatty acids, so energy consumption increases and has a weight loss effect. In addition, it is reported that when a person's body temperature is high, the amount of physical and mental operations and the accuracy of their operations also increase, so these operational abilities improve.

[0097] If the activity of the sympathetic nerves that control the adrenal glands increases, the release of adrenaline and norepinephrine from the adrenal medulla into the blood (endocrine) is promoted. As a result, the response of organs and tissues in the body is determined by the type of adrenaline receptors located in these parts. Generally speaking, if the adrenal sympathetic nerves are promoted, the secretion of adrenaline and norepinephrine will be improved, and the function of the heart, energy mobilization, activity level, etc. will be improved.

[0098] If the activity of the sympathetic nerves controlling the liver increases, the parasympathetic nerves controlling the liver are inhibited. In this way, glycogenolytic enzymes are activated, and glucose produced by glycogenolysis is released into the blood. At the same time, glycogenolysis in the liver is promoted, thereby increasing the glucose supply to the whole body.

[0099] Therefore, the present invention also relates to a lipolysis promoter, a fat accumulation inhibitor, or an activity promoter for increasing the activity level of an individual, comprising the compound represented by the above structural formula (1). In addition, it also relates to a composition for promoting lipolysis comprising the above lipolysis promoter, a composition for inhibiting fat accumulation comprising the above fat accumulation inhibitor, or an activity promoting composition comprising the above activity promoter. Further, it also relates to a method for promoting lipolysis, characterized in that at least one selected from the group consisting of the above lipolysis promoter and the composition for promoting lipolysis is administered to an individual; a method for inhibiting fat accumulation, characterized in that at least one selected from the group consisting of the above fat accumulation inhibitor and the composition for inhibiting fat accumulation is administered to an individual; or an activity promoting method for increasing the activity level of an individual, characterized in that at least one selected from the group consisting of the above activity promoter and the composition for promoting activity is administered to an individual.

[0100] Example

[0101] Hereinafter, test examples and formulation examples of the present invention will be described, but the present invention is not limited to these test examples and formulation examples.

[0102] (Test Example 1)

[0103] The effect of intragastric administration of the compound represented by the above structural formula (1) on the activity of sympathetic nerves controlling white adipose tissue, brown adipose tissue, adrenal glands, or liver was tested as follows.

[0104] <Measurement>

[0105] The experiment was conducted in a 24°C constant temperature animal room with a light-dark cycle of 12 hours (lights on until 8:00-20:00), using Wistar male rats (about 9 weeks old) weighing about 300 g that had been raised for more than one week. On the day of the experiment, the rats were fasted for 3 hours, anesthetized with urethane, and a cannula for intragastric administration was inserted. Then, the centrifugal branches of the sympathetic nerves that control the right epididymis white adipose tissue, interscapular brown adipose tissue, left adrenal gland, or liver were suspended with silver electrodes, and their electrical activities were measured.

[0106] During the stable period of their measured values ​​(around 13:00), an aqueous solution of the compound represented by the above structural formula (1) (manufactured by Tokyo Chemical Industry) was administered intragastrically using a cannula at a dosage of 15 mg / 0.5 mL / 300 g body weight, 1.5 mg / 0.5 mL / 300 g body weight, 0.15 mg / 0.5 mL / 300 g body weight, or 0.015 mg / 0.5 mL / 300 g body weight, and the changes in the nerve activity of the centrifugal branches of the sympathetic nerves were electrophysiologically measured for 60 minutes. In addition, as a control, water as a solvent was administered intragastrically using a cannula at a dosage of 0.5 mL / 300 g body weight, and the changes in the nerve activity of the centrifugal branches of the sympathetic nerves were electrophysiologically measured for 60 minutes.

[0107] From the start of surgery until the end of measurement, a tube was inserted into the trachea to secure the airway, and the body temperature (rat rectal temperature) was maintained at 37.0±0.5°C in a warming device.

[0108] The data of neural activity were analyzed as the average value of the firing frequency (pulse / 5s) for 5 seconds every 5 minutes, and expressed as a percentage with the average value (0 score) for 5 minutes before the start of stimulation being 100%.

[0109] <Results>

[0110] - White adipose tissue -

[0111] The results are shown in Table 1. Changes in the nerve activity of the epididymal white adipose tissue sympathetic nerve centrifugal branches (WAT-SNA) when an aqueous solution containing 15 mg or 1.5 mg of the compound represented by the above structural formula (1) at a dosage of 0.5 mL / 300 g body weight or water as a solvent at a dosage of 0.5 mL / 300 g body weight was intragastrically administered. The results are shown in Table 1. Changes in the nerve activity of the epididymal white adipose tissue sympathetic nerve centrifugal branches (WAT-SNA) when an aqueous solution containing 15 mg or 1.5 mg of the compound represented by the above structural formula (1) at a dosage of 0.5 mL / 300 g body weight or water as a solvent at a dosage of 0.5 mL / 300 g body weight were intragastrically administered. The results are shown in Table 1. Figure 1 .

[0112] Figure 1As shown, an aqueous solution containing 15 mg of the compound represented by the above structural formula (1) was administered at a dose of 0.5 mL / 300 g body weight to the group ( Figure 1 "◆" in the figure) and a group ( Figure 1 In the group ( Figure 1 The results show that the compound represented by the structural formula (1) has an effect of activating the activity of the sympathetic nerves that control white adipose tissue.

[0113] When the activity of the sympathetic nerves that control white adipose tissue increases, the lipase of the white adipose tissue is activated through the β3 adrenergic receptors, promoting lipolysis that breaks down the accumulated neutral fat into fatty acids and glycerol, thereby having a slimming effect of reducing the amount of fat accumulation.

[0114] - Brown adipose tissue -

[0115] The results of changes in the nerve activity of the sympathetic nerve centrifugal branches of the interscapular brown adipose tissue (BAT-SNA) when 15 mg, 1.5 mg, or 0.15 mg of an aqueous solution containing the compound represented by the above structural formula (1) was intragastrically administered at a dosage of 0.5 mL / 300 g body weight, or water as a solvent was intragastrically administered at a dosage of 0.5 mL / 300 g body weight, with the average value of the nerve activity in the first 5 minutes before intragastrically administered (0 score) being 100% as a percentage are shown in Figure 2 .

[0116] Figure 2 As shown, an aqueous solution containing 15 mg of the compound represented by the above structural formula (1) was administered at a dose of 0.5 mL / 300 g body weight to the group ( Figure 2 The group ( Figure 2 ), and a group to which an aqueous solution containing 0.15 mg of the compound represented by the above structural formula (1) was administered at a dose of 0.5 mL / 300 g body weight ( Figure 2 In the group ( Figure 2From this result, it can be seen that the compound represented by the structural formula (1) has the effect of activating the activity of the sympathetic nerves that control the brown adipose tissue.

[0117] If the activity of the sympathetic nerves that control brown adipose tissue increases, the uncoupling protein-1 (UCP-1) present in the mitochondria of brown adipose tissue is activated through the β3 adrenergic receptor, promoting heat generation and raising body temperature. The heat generation of this tissue uses fatty acids, so energy consumption increases and has a slimming effect. In addition, it is reported that when a person's body temperature is high, the amount of physical and mental operations and the accuracy of their operations also increase, so these operational abilities improve.

[0118] -Adrenal glands-

[0119] The results are shown in Table 1. Changes in adrenal sympathetic nerve activity (ASNA) in the centrifugal branches of the adrenal sympathetic nerve when 15 mg, 1.5 mg, 0.15 mg, or 0.015 mg of an aqueous solution containing the compound represented by the above structural formula (1) at a dosage of 0.5 mL / 300 g body weight or water as a solvent at a dosage of 0.5 mL / 300 g body weight were intragastrically administered. The results are shown in Table 1. Figure 3 .

[0120] Figure 3 As shown, an aqueous solution containing 15 mg of the compound represented by the above structural formula (1) was administered at a dose of 0.5 mL / 300 g body weight to the group ( Figure 3 The group ( Figure 3 ), an aqueous solution containing 0.15 mg of the compound represented by the above structural formula (1) was administered at a dose of 0.5 mL / 300 g body weight to the group ( Figure 3 ), and a group in which an aqueous solution containing 0.015 mg of the compound represented by the above structural formula (1) was administered at a dose of 0.5 mL / 300 g body weight ( Figure 3 In the group ( Figure 3 The ASNA value is higher than that of the compound represented by the structural formula (1). This result shows that the compound represented by the structural formula (1) has the effect of activating the activity of the sympathetic nerves that control the adrenal glands.

[0121] If the activity of the sympathetic nerves that control the adrenal glands increases, the release of adrenaline and norepinephrine from the adrenal medulla into the blood (endocrine) is promoted. As a result, the response of organs and tissues in the body is determined by the type of adrenaline receptors located in these parts. Generally speaking, if the adrenal sympathetic nerves are promoted, adrenaline and norepinephrine are secreted, and the function of the heart, energy mobilization, activity level, etc. are improved. Therefore, the administration of the compound represented by the above structural formula (1) has the effect of promoting the secretion of adrenaline and norepinephrine from the adrenal medulla, improving the function of the heart, energy mobilization, activity level, etc.

[0122] -liver-

[0123] The results are shown in Table 1. Changes in hepatic sympathetic nerve activity (Hepatic-SNA) when an aqueous solution containing 15 mg, 1.5 mg, or 0.15 mg of the compound represented by the above structural formula (1) at a dosage of 0.5 mL / 300 g body weight or water as a solvent at a dosage of 0.5 mL / 300 g body weight were intragastrically administered. The results are shown as a percentage of the average value (0 score) of the nerve activity in the first 5 minutes before intragastrically administering the compound represented by the above structural formula (1) as 100%. Figure 4 .

[0124] Figure 4 As shown, an aqueous solution containing 15 mg of the compound represented by the above structural formula (1) was administered at a dose of 0.5 mL / 300 g body weight to the group ( Figure 4 The group ( Figure 4 ), and a group to which an aqueous solution containing 0.15 mg of the compound represented by the above structural formula (1) was administered at a dose of 0.5 mL / 300 g body weight ( Figure 4 In the group ( Figure 4 The results show that the compound represented by the structural formula (1) has an effect of activating the activity of the sympathetic nerves that control the liver.

[0125] If the activity of the sympathetic nerves that control the liver increases, the parasympathetic nerves that control the liver are inhibited. In this way, glycogenolytic enzymes are activated, and glucose produced by glycogenolysis is released into the blood. At the same time, gluconeogenesis in the liver is promoted, increasing the glucose supply to the whole body.

[0126] (Matching Example 1)

[0127] Tablets having the following composition were produced by a conventional method.

[0128]

[0129] (Matching Example 2)

[0130] An oral liquid preparation having the following composition was produced by a conventional method.

[0131] <Composition in 1 ampoule (1 bottle 100mL)>

[0132]

[0133] (Matching Example 3)

[0134] By a conventional method, a coffee beverage having the following composition was produced.

[0135]

[0136] (Matching Example 4)

[0137] A capsule having the following composition was produced by a conventional method. In addition, a No. 1 hard gelatin capsule was used as the capsule.

[0138] <Composition of 1 capsule (200 mg per capsule)>

[0139]

[0140] This application claims priority based on Japanese Patent Application No. 2022-079685 filed on May 13, 2022, and the entire contents of Japanese Patent Application No. 2022-079685 are incorporated herein by reference.

Claims

1. A sympathetic nerve activator, characterized in that Contains a compound represented by the following structural formula (1):

2. The sympathetic nerve activator according to claim 1, The sympathetic nerve is a sympathetic nerve that controls at least one selected from the group consisting of white adipose tissue, brown adipose tissue, adrenal glands, and liver.

3. A composition for sympathetic nerve activation, characterized in that Contains the sympathetic nerve activator according to claim 1 or 2.

Images